Lawmakers Eye Biosimilar-Delay Deals, But None Are Here Yet
Pay-for-delay deals staving off generic competition have become a favorite target for lawmakers eager to be seen combating soaring pharmaceutical costs and for antitrust enforcers who believe consumers are hurt when...To view the full article, register now.
Already a subscriber? Click here to view full article